Safety of HMG-CoA reductase inhibitors: focus on atorvastatin

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Statins are a class of drugs widely used to lower LDL-cholesterol.
• They are prescribed to patients with or at risk for coronary heart disease to reduce cardiovascular events and mortality.
• Understanding the safety profile of statins is crucial for long-term patient management.

Purpose of the Study:

• To review the safety and tolerability of statins.
• To highlight common and rare adverse events associated with statin therapy.
• To discuss drug interactions and specific considerations for atorvastatin.

Main Methods:

• Review of existing literature on statin efficacy and safety.
• Analysis of reported adverse events, including gastrointestinal symptoms, elevated transaminases, and myopathy.
• Examination of factors influencing statin safety, such as drug interactions and patient populations.

Main Results:

• Statins effectively reduce LDL-cholesterol and cardiovascular risk.
• Most patients tolerate statins well, with low withdrawal rates (<3%) due to adverse events.
• Common side effects are mild gastrointestinal issues; serious adverse events like myopathy and rhabdomyolysis are very rare.
• Elevated transaminases are infrequent, asymptomatic, reversible, and rarely necessitate drug discontinuation.
• Statins do not negatively impact endocrine function, glycemic control in diabetics, or cancer risk.

Conclusions:

• Statins possess a favorable safety profile with significant cardiovascular benefits.
• Careful consideration of drug interactions is necessary, especially with concomitant medications.
• Atorvastatin demonstrates good long-term tolerability and a safety profile comparable to other statins.